Computational drug Cumintrazole-analog for the treatment of mutant BRCA1 and BRCA2 proteins in breast cancer

Authors

  • Shehneela Baseer Department of Bioinformatics Government Postgraduate College Mandian Abbottabad
  • Sajid Khan Department of Bioinformatics Government Postgraduate College Mandian Abbottabad
  • Faisal Nouroz Department of Bioinformatics Hazara University Mansehra

DOI:

https://doi.org/10.3329/icpj.v4i8.24021

Keywords:

BRCA1, BRCA2, breast cancer, in-silico, mutation

Abstract

Breast cancer is the second death causing disease in the world. Breast cancer gene 1 (BRCA1) and Breast cancer gene 2 (BRCA2) are the controlling proteins of this cancer. Real capacity of BRCA1/BRCA2 is to control the cell division, repair the damaged DNA and stabilized the genetic material of the cell. In case of any mutation in these proteins, the division of breast cells will be modified and therefore the cancerous development of cells will start in breast. The essential target of study was to prepare novel synthetic compound to focus on destinations for receptor proteins, located on cells surface, which control the development or stop the multiplication of cancer cells. Subsequent to screening vast measure of information, we outlined novel in-silico medication compound for breast cancer that is able to hinder the uncontrolled development of cells. In docked edifices PHE and GLN are critical communicating build ups for BRCA1 and BRCA2 proteins. Atomic recipe of shad sample totally fulfills the Lipinski rule of five. It shows less symptoms and long resistance against breast cancer cells. We infer that our medication shad sample is better than the business drugs available in business sector. As it is non-toxic in nature and has no reactions. The proposed drug is suitable for reduction of the breast cancer in females.

Baseer et al., International Current Pharmaceutical Journal, July 2015, 4(8): 410-414

Downloads

Download data is not yet available.
Abstract
149
PDF
106

Downloads

Published

2015-07-06

How to Cite

Baseer, S., Khan, S., & Nouroz, F. (2015). Computational drug Cumintrazole-analog for the treatment of mutant BRCA1 and BRCA2 proteins in breast cancer. International Current Pharmaceutical Journal, 4(8), 410–414. https://doi.org/10.3329/icpj.v4i8.24021

Issue

Vol. 4 No. 8 (2015)

Section

Original Articles

License

Authors who publish with this journal agree to the following terms:

  1. The journal holds copyright and publishes the work under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
  2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
  3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).